ScholarIQanswers from OpenAlex & ORCID
Wenfeng Fang
ResearcherPublications, citations & collaboration network
Wenfeng Fang is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Wenfeng Fang have?
ScholarIQindexed works
Wenfeng Fang has 431 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Wenfeng Fang have?
ScholarIQcitation count
Wenfeng Fang has 10,218 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Wenfeng Fang?
ScholarIQh-index
Wenfeng Fang has an h-index of 48 in OpenAlex.
What is the i10-index of Wenfeng Fang?
ScholarIQi10-index
Wenfeng Fang has an i10-index of 159 in OpenAlex.
What is the ORCID of Wenfeng Fang?
ScholarIQorcid
The ORCID for Wenfeng Fang is on the source record.
What is the OpenAlex record for Wenfeng Fang?
ScholarIQopenalex
The OpenAlex for Wenfeng Fang is on the source record.
What are the most-cited papers on Wenfeng Fang?
ScholarIQmost cited works
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen, Wenfeng Fang, Jianhua Zhan, Shaodong Hong, Yanna Tang, Shiyang Kang, Yaxiong Zhang, Xiaobo He, Ting Zhou, Tao Qin, Yan Huang, Xianping Yi, Li Zhang
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
Wenfeng Fang, Yunpeng Yang, Yuxiang Ma, Shaodong Hong, Lizhu Lin, Xiaohui He, Jianping Xiong, Ping Li, Hongyun Zhao, Yan Huang, Yang Zhang, Likun Chen, Ningning Zhou, Yuanyuan Zhao, Xue Hou, Qing Yang, Li Zhang
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Yunpeng Yang, Song Qu, Jingao Li, Chaosu Hu, Mingjun Xu, Weidong Li, Ting Zhou, Liangfang Shen, Hui Wu, Jinyi Lang, G. Hu, Zhanxiong Luo, Zhichao Fu, Shenhong Qu, Weineng Feng, Xiaozhong Chen, Shaojun Lin, Weimin Zhang, Xiaojiang Li, Yan Sun, Zhixiong Lin, Qin Lin, Lei Feng, Jianting Long, Jinsheng Hong, Xiaoming Huang, Lingzhi Zeng, Peiguo Wang, Xiaohui He, Ben Zhang, Qing Yang, Xiao‐Jing Zhang, Jianjun Zou, Wenfeng Fang, Li Zhang
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
Wenfeng Fang, Jianwei Zhang, Shaodong Hong, Jianhua Zhan, Nan Chen, Tao Qin, Yanna Tang, Yaxiong Zhang, Shiyang Kang, Ting Zhou, Xuan Wu, Wenhua Liang, Zhihuang Hu, Yuxiang Ma, Yuanyuan Zhao, Ying Tian, Yunpeng Yang, Cong Xue, Yue Yan, Xue Hou, Pei-Yu Huang, Yan Huang, Hongyun Zhao, Li Zhang
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
Nan Chen, Wenfeng Fang, Lin Zhong, Peijian Peng, Juan Wang, Jianhua Zhan, Shaodong Hong, Jiaxing Huang, Lin Liu, Sheng Jin, Ting Zhou, Ying Chen, Hongyu Zhang, Li Zhang